Navigation Links
FDA Asserts New Policy to Restrict Women's Access to Bioidentical Hormones
Date:1/9/2008

Agency Warns Pharmacies Not to Compound Commonly Prescribed Hormone Treatments, Use the Term "Bio-identical"

MISSOURI CITY, Texas, Jan. 9 /PRNewswire-USNewswire/ -- In a series of warning letters to compounding pharmacies across the country, the Food and Drug Administration (FDA) has asserted a policy that would deny hundreds of thousands of women access to many compounded bioidentical hormones commonly, substituting its judgment for that of doctors. Wyeth Pharmaceuticals, the number one manufacturer of synthetic hormone products, petitioned the FDA to do so in October 2005. More than 66,000 doctors, patients, and pharmacists filed comments with the FDA opposing Wyeth's petition.

"Under this policy, patients will suffer while Wyeth profits," said L.D. King, executive director of the International Academy of Compounding Pharmacists (IACP). "Thousands of doctors are making patient-by-patient decisions that compounded hormones are medically appropriate, sometimes because Wyeth's products are found to be ineffective or produce side effects. This is a decision that should be left to doctors."

In the letters, the FDA states that it will "halt" compounding of medications containing estriol, an estrogen produced by the human body. Estriol is one of the most widely prescribed hormones and is regularly compounded with other bio-identical hormones pursuant to doctors' prescriptions for women suffering from symptoms of menopause. Like many commonly prescribed drugs (e.g, Phenobarbital, quinine, tinidazole), estriol has a monograph from the U.S. Pharmacopeia (USP), but is not a component of an FDA-approved drug. When it passed the FDA Modernization Act in 1997, Congress clearly indicated that drugs with a USP monograph could be compounded.

The FDA also stated in its letters that pharmacies may not use the term "bio-identical" to characterize compounded hormone therapies, even though the chemicals used in such compounds are chemically id
'/>"/>

SOURCE International Academy of Compounding Pharmacists
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Donde West Death Highlights Unnecessary Risk of General Anesthesia for Cosmetic Surgery, Asserts Dr. Friedberg
2. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
3. Chinas 1-child policy could backfire on its elderly
4. Education Key Focus of Michigan Policy Summit
5. Consumer Group: Hillary Clintons Mandatory Health Insurance Purchase Plan is an Act of War on the Middle Class Family That Cant Afford $12k Policy
6. SATELLITE BROADCAST: Consumer Group Says Hillary Clintons Mandatory Health Insurance Plan is an Act of War on the Middle Class that Cant Afford $12k Policy
7. First-in-the-Nation Health Care Billing Policy Announced in Minnesota
8. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
9. Global Leaders Converge for Special Olympics Global Policy Summit
10. Wellpoint NextRx Receives TIPPS Certification from the HR Policy Association
11. National Medical Association Selects New Director of Health Policy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... News) -- The risk of burns from fires and ... to be extra cautious, an expert says. "Between ... increase in patients coming in with burns," said Dr. ... Firefighters Burn Center of Stony Brook University Hospital in ... joy, but if not careful, could quickly turn tragic," ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
(Date:12/25/2014)... 2014 “ SmileStix ” was featured on ... latest and coolest mobile applications on the iOS, Android, and ... of NewsWatch, conducted the app review and shared with viewers ... stickers. , The old saying goes, “A picture says a ... that can describe a single image, because each picture holds ...
(Date:12/25/2014)... Each year trauma accounts for approximately ... admissions across the nation (according to the Centers ... National Hospital Ambulatory Medical Care Survey collected data ... 2010. They estimated that there were between 3.5 and ... primary diagnosis of broken bone or fracture. , ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 Over 700 ... to their local communities. That is 700 smiling little ... single gift. Additionally over $6000 in monetary donations was ... offset some of the expenses they incur through the ... drive were A Child's Haven , Shrine's Children's ...
Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife Donates Over 700 Toys This Year 2
... that acupuncture provided significant reductions in pain, dysfunction, and ... neck dissection. The study was led by David Pfister, ... Service, and Barrie Cassileth, PhD, Chief of the Integrative ... Pfister presented the findings today at the annual meeting ...
... Phase II studies demonstrated potential for pazopanib as a single,agent treatment for ... -- In patients with stage I-III non-small cell lung cancer, 86 ... experienced a reduction in tumor volume ... overall response rate of 35 percent. The ...
... -- Leading oncologists and cancer researchers at NewYork-Presbyterian ... and clinical research findings at the 44th American ... Chicago, May 30 to June 3. , Highlights ... made by NewYork-Presbyterian/Weill Cornell physician-scientists include the following: ...
... to some experts, newly born neuronal stem cells in the ... if these stem cells are to be utilized in this ... be regulated. , A new study, led by Laurence ... University of the North Carolina School of Medicine, suggests a ...
... SCREENING FOR THE RISKS OF LIFE-THREATENING FALLS" ... strong connection between the cognitive function of their elderly ... , The study, which is in line with ... balance, also found a brief questionnaire designed to probe ...
... American,Physicians, Inc. (CAP) today announced that the exceptional financial,strength ... again,earned an A+ rating from A.M. Best Company, a ... year that MPT has,achieved this rating., "We are ... again this year,",said CEO James L. Weidner. "It validates ...
Cached Medicine News:Health News:Acupuncture reduces pain and dysfunction in head and neck cancer patients after neck dissection 2Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 2Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 3Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 4Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 5Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 6Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 7Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 8Health News:NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting 2Health News:NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting 3Health News:NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting 4Health News:Indiana University research at the American College of Sports Medicine annual conference 2Health News:Indiana University research at the American College of Sports Medicine annual conference 3Health News:Indiana University research at the American College of Sports Medicine annual conference 4Health News:Indiana University research at the American College of Sports Medicine annual conference 5Health News:Indiana University research at the American College of Sports Medicine annual conference 6Health News:Indiana University research at the American College of Sports Medicine annual conference 7Health News:Mutual Protection Trust Earns Third A+ Rating From A.M. Best 2
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
(Date:12/24/2014)... and FARMINGTON, Conn. , ... (NYSE MKT: PTN), a biopharmaceutical company developing targeted, ... with significant unmet medical need and commercial potential, ... private placement of 2,050,000 shares of its common ... shares of its common stock.  Funds under the ...
(Date:12/24/2014)... , Dec. 23, 2014 ResMed (NYSE: ... patent infringement action against Chinese medical device manufacturer BMC Medical ... ruled today that BMC,s masks listed below infringe ResMed,s patents, ... selling these masks in the United States ... N2 nasal mask , Willow nasal pillows mask ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... that a new market research report is available in ... Drug Delivery System http://www.reportlinker.com/p0337136/Chinese-Markets-for--Drug-Delivery-System.html ... System has grown at a fast pace in the ... and demand will continue to grow. This new study ...
... 9, 2010 Reportlinker.com announces that ... catalogue: Prostate Cancer - Italy Drug ... http://www.reportlinker.com/p0332355/Prostate-Cancer---Italy-Drug-Forecasts-and-Treatment-Analysis-to-2020.html Prostate Cancer - Italy ... SummaryGlobalData,s pharmaceutical report, "Prostate Cancer - Italy Drug ...
Cached Medicine Technology:Reportlinker Adds Chinese Markets for Drug Delivery System 2Reportlinker Adds Chinese Markets for Drug Delivery System 3Reportlinker Adds Chinese Markets for Drug Delivery System 4Reportlinker Adds Chinese Markets for Drug Delivery System 5Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 2Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 3Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 4Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 5Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 6Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 7Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 8Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 9Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 10Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 11Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 12Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 13Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 14
... laboratories that have decided to change to the ... the RELISA ANAs correlation with IFA and many ... competition. While no ELISA ANA currently on the ... our RELISA ANA screen has been shown to ...
... HEp-2 cell line that has been genetically ... autoantibodies, without affecting the other ANA patterns ... worldwide on the HEp-2000 ANA substrate, which ... used in place of standard HEp-2 cells ...
... ENA assays can be used to ... antibodies, which are associated with various ... lupus erythematosus (Lupus), Sjgren's syndrome, mixed ... scleroderma, polymyositis, dermatomyositis, and Raynaud's phenomenon. ...
... Indirect Fluorescence Assay (IFA) for Anti-native ... for the qualitative and semi-quantitative detection ... nDNA in human serum. Detection of ... be used as an aid in ...
Medicine Products: